There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palatin Technologies (PTN) and Clovis Oncology (CLVS) with bullish sentiments.
Palatin Technologies (PTN)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Palatin Technologies, with a price target of $5. The company’s shares closed yesterday at $0.77.
Pantginis commented:
“Our thesis on shares remains unchanged; major boxes checked and valuation disconnect exists, in our belief. Significant boxes have already been checked off, which we believe provide a derisked opportunity for investors.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -20.3% and a 25.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Palatin Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Clovis Oncology (CLVS)
In a report released today, Edward White from H.C. Wainwright initiated coverage with a Buy rating on Clovis Oncology and a price target of $40. The company’s shares closed yesterday at $25.19.
White noted:
“We derive our $40 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination, prostate, and bladder cancer indications, and the net present value for the current commercial business. We use the net present value (NPV) of our revenue forecasts through 2028, apply a 40% probability of success (POS) for Rubraca in ovarian combination, 45% POS for Rubraca in prostate cancer, and 15% POS for Rubraca in bladder cancer.”
According to TipRanks.com, White is a 5-star analyst with an average return of 13.7% and a 45.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The the analyst consensus on Clovis Oncology is currently a Moderate Buy rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
